Supernus Pharmaceuticals Inc
F:S49
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Supernus Pharmaceuticals Inc
F:S49
|
US |
|
A
|
Avalon Technologies Ltd
BSE:543896
|
IN |
|
W
|
Woolworths Holdings Ltd
XBER:WN3
|
ZA |
|
Y
|
Yangzijiang Maritime Development Pte Ltd
SGX:8YZ
|
SG |
|
Dundee Sustainable Technologies Inc
OTC:DNDDF
|
CA |
|
P
|
Polygiene Group AB
STO:POLYG
|
SE |
|
SKF AB
F:SKFB
|
SE |
|
Adicet Bio Inc
F:1IJA
|
US |
|
I
|
InterDigital Inc
SWB:IDI
|
US |
|
R S Software (India) Ltd
NSE:RSSOFTWARE
|
IN |
|
SLM Corp
NASDAQ:SLM
|
US |
|
T
|
Transgene SA
SWB:TGNA
|
FR |
|
D
|
Deyun Holding Ltd
HKEX:1440
|
CN |
|
S
|
Sunrun Inc
SWB:3S9
|
US |
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals is a specialty drug company that makes prescription medicines for central nervous system disorders, especially attention deficit hyperactivity disorder, epilepsy, migraine, and movement disorders. Its main products are branded medicines sold through pharmacies to patients with prescriptions from doctors. The company earns money when wholesalers and pharmacies buy those drugs and move them into the prescription chain. Its customer base is mostly patients, prescribers, pharmacies, and drug wholesalers, with doctors playing a key role because they decide which treatment to use. Supernus also develops and markets medicines that can be taken on a regular schedule or in specific long-acting forms, which matters in conditions where steady symptom control is important. In some cases, it also works with other drug companies through licensing or commercialization agreements. What makes Supernus different is that it focuses on a narrow set of brain and nervous system conditions rather than a broad menu of medicines. That gives it a business built around a few specialized brands, close relationships with doctors who treat these disorders, and a strong dependence on prescription demand and patent-protected products.
Supernus Pharmaceuticals is a specialty drug company that makes prescription medicines for central nervous system disorders, especially attention deficit hyperactivity disorder, epilepsy, migraine, and movement disorders. Its main products are branded medicines sold through pharmacies to patients with prescriptions from doctors. The company earns money when wholesalers and pharmacies buy those drugs and move them into the prescription chain.
Its customer base is mostly patients, prescribers, pharmacies, and drug wholesalers, with doctors playing a key role because they decide which treatment to use. Supernus also develops and markets medicines that can be taken on a regular schedule or in specific long-acting forms, which matters in conditions where steady symptom control is important. In some cases, it also works with other drug companies through licensing or commercialization agreements.
What makes Supernus different is that it focuses on a narrow set of brain and nervous system conditions rather than a broad menu of medicines. That gives it a business built around a few specialized brands, close relationships with doctors who treat these disorders, and a strong dependence on prescription demand and patent-protected products.
Top line: Supernus reported first-quarter revenue of $207.7 million, up 39% year over year, driven by strong growth across its marketed products and a $20 million licensing milestone from Shunovi.
ONAPGO rebound: ONAPGO sales reached $8.4 million as patient initiations resumed in February, and management said March metrics recovered to or above pre-supply-constraint levels.
Guidance held: The company reiterated full-year 2026 guidance, including revenue of $840 million to $870 million and non-GAAP operating earnings of $140 million to $170 million.
Qelbree strength: Qelbree continued to outgrow the ADHD market, with prescriptions up 19% and net sales up 20%, while adult adoption accelerated.
ZURZUVAE momentum: ZURZUVAE collaboration revenue was $27.6 million, with prescriptions up 82% and prescribers up 73% year over year; management said the brand is still early in its growth runway.
Balance sheet: Cash, cash equivalents and marketable securities rose to about $384 million, and the company emphasized its no-debt position and M&A flexibility.
